Available here are the presentation slides and video recordings from the Friday, September 6, 2019 Adoptive Cellular Therapies Workshop.In the wake of the 2017 U.S. Food and Drug Administration approvals for Chimeric Antigen Receptor (CAR) T cell therapies for the treatment of patients with lymphoma and leukemia, adoptive cellular therapies have rapidly become a focal point for stakeholders across the field of cancer immunotherapy. As this treatment modality has displayed unprecedented patient response and offers significant curative potential for cancer patients across the globe, SITC hosted an Adoptive Cellular Therapies Workshop to support both continued momentum and clinical advancement. This two-day workshop brought together cancer immunotherapy experts to discuss and address challenges concerning the use and development of adoptive cellular therapies for the treatment of cancer patients.Program Organizers:
Meeting: Adoptive Cellular Therapies Workshop; Chair: John M. Rossi, MS – Kite, A Gilead Company; Date: September 6, 201900:37:34
Meeting: Adoptive Cellular Therapies Workshop; Presenter: Prasad S. Adusumilli, MD, FACS, FCCP – Memorial Sloan Kettering Cancer Center; Date: September 6, 201900:24:37
Meeting: Adoptive Cellular Therapies Workshop; Presenter: May Daher, MD – The University of Texas MD Anderson Cancer Center; Date: September 6, 201900:20:08
Meeting: Adoptive Cellular Therapies Workshop; Presenter: Andrew W. Harmon, PhD – U.S. Food and Drug Administration; Date: September 6, 201900:16:49
Join
Renew
Member Directory
My Profile
Email Sign-up
Volunteer
Support SITC
Contact Us